Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IO102 · 1 trial · 1 indication
Dose Limiting Toxicity graded per Common Terminology Criteria for Adverse Events (CTCAE) version 4.03
Objective Response Rate (ORR) evaluated by RECIST 1.1 and defined as the rate of complete response (CR) + partial response (PR)
| Arm | Type | Description |
|---|---|---|
| Cohort A1 | EXPERIMENTAL | Drug: IO102 100µg administered subcutaneously (SC) on Day 1 of each 3 week cycle PLUS Drug: pembrolizumab (Keytruda) 200 mg intravenous (IV) infusion on Day 1 of each 3 week cycle |
| Cohort A2 | ACTIVE_COMPARATOR | Drug: pembrolizumab (Keytruda) 200 mg IV infusion on Day 1 of each 3 week cycle |
| Cohort B1 | EXPERIMENTAL | Drug: IO102 100µg SC on Day 1 of each 3 week cycle PLUS Drug: pembrolizumab (Keytruda) 200 mg IV on Day 1 of each 3 week cycle PLUS Drug: carboplatin (Carboplatin Kabi) at a target AUC of 5 mg/mL IV infusion on Day 1 of each 3 week cycle for a max of 4 administrations PLUS Drug: pemetrexed (Pemetrexed Alvogen) at 500 mg/m2 IV infusion on Day 1 of each 3 week cycle |
| Cohort B2 | ACTIVE_COMPARATOR | Drug: pembrolizumab (Keytruda) 200 mg IV on Day 1 of each 3 week cycle PLUS Drug: carboplatin (Carboplatin Kabi) at a target AUC of 5 mg/mL IV infusion on Day 1 of each 3 week cycle for a max of 4 administrations PLUS Drug: pemetrexed (Pemetrexed Alvogen) at 500 mg/m2 IV infusion on Day 1 of each 3 week cycle |
| Name | Type | Description |
|---|---|---|
| IO102 | BIOLOGICAL | test immunotherapy |
| pembrolizumab (Keytruda) | BIOLOGICAL | anti-PD-1 immunotherapy |
| Carboplatin (Carboplatin Kabi) | DRUG | chemotherapy |
| Pemetrexed (Pemetrexed Alvogen) | DRUG | chemotherapy |
Inclusion Criteria: * Histologically or cytologically confirmed metastatic NSCLC or non squamous NSCLC * Have biomarker-positive solid tumor * Male participants of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study medication through 1...
IO102 is an investigational therapeutic vaccine developed by IO Biotech for non-small cell lung cancer (NSCLC). It is designed to target PD-L1, a protein found on tumor and immune cells. IO102 has been studied in a Phase 1/2 clinical trial as a first-line treatment for metastatic NSCLC, in combination with pembrolizumab with or without chemotherapy.
IO102 targets PD-L1, a protein target. By directing an immune response against cells expressing PD-L1, the vaccine approach is intended to act on this protein target. PD-L1 is also the target of checkpoint inhibitor therapies, and IO102 was studied alongside pembrolizumab in metastatic NSCLC.
IO102 is being developed by IO Biotech, Inc., which trades under the ticker IOBTQ. The company is the sponsor of the clinical program evaluating IO102 in non-small cell lung cancer.
IO102 is in Phase 1/2 clinical development and is investigational. Its single recorded trial, NCT03562871, is a Phase 1/Phase 2 study that has been completed. IO102 has been evaluated in metastatic NSCLC as a first-line treatment combined with pembrolizumab, with or without chemotherapy.
IO102 has been studied in trial NCT03562871, titled "IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC." The Phase 1/Phase 2 trial enrolled 109 patients across Germany, the Netherlands, Spain, and the United Kingdom, was randomized and active-controlled, and has completed.
IO102 is being studied for non-small cell lung cancer (NSCLC), specifically as a first-line treatment for metastatic disease. In trial NCT03562871 it was given with pembrolizumab, with or without chemotherapy, in adults 18 years and older. IO102 remains investigational and is not established as an approved therapy.